CompletedPhase 3

Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.

Pakistan30 participantsStarted 2023-07-01

Plain-language summary

To determine the efficacy of oral Tofacitinib in the treatment of moderate to severe alopecia areata, totalis and universalis at tertiary care hospital of Karachi, Pakistan. Efficacy of treatment in patients presenting with alopecia areata will be assessed using SALT Score on follow up at 6,12 and 24 weeks where four categories of treatment response were defined: 0 (re-growth ≤10%), 1 (11-25%), 2 (26-50%), 3 (51-75%) and 4 (re-growth \>75%). Efficacy will be considered if re-growth ≥ 2.

Who can participate

Age range15 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients presenting with Alopecia areata as per operational definition will be included in the study. * Either gender. * Age 15 - 60 years. Exclusion Criteria: * Patient with history of connective tissue disorders, vasculitis, seropositive and seronegative arthritis. * Patients having history of treatment with systemic agents, having active infection, pregnant and lactating women and patients having severe hematological abnormalities. * Patients positive for latent infections. * Patients with weight \<25 kg.

What they're measuring

Alopecia

Timeframe: 6 months

Trial details

NCT IDNCT06278402

SponsorJinnah Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-01-06

View on ClinicalTrials.gov More Alopecia Areata trials